Annotation Detail
Information
- Associated Genes
- PTEN
- Associated Variants
-
PTEN MUTATION
PTEN MUTATION - Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- IC50 for the pan-Akt inhibitor ipatasertib (GDC-0068) was determined over a panel of 100 cancer cell lines. Loss or mutation of PTEN (e.g. PTEN deletion, T319fsX1/Y155C, etc.) was significantly associated with ipatasertib sensitivity (p=0.000071). Non-transformed human mammary epithelial MCF10A cells were compared to an isogenic line with PTEN knockout. With low or high EGF culture conditions, a 4x or 3.5x decrease in IC50 for ipatasertib was seen in PTEN knockout cells, respectively.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1491
- Gene URL
- https://civic.genome.wustl.edu/links/genes/41
- Variant URL
- https://civic.genome.wustl.edu/links/variants/510
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Ipatasertib
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23287563
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ipatasertib | Sensitivity | true |